2024 Rome, Italy

II-49 Naoki Kotani
A model based approach to infer overall survival (OS) in hormone receptor positive (HR+) human epidermal growth factor receptor 2 negative (HER2-) metastatic breast cancer (HR+/HER2- mBC)